New Multileaf Collimator Reduces Treatment Time for CyberKnife Candidates; Can More Efficiently Treat Unusual-shaped Tumors
The second patient in the world has received treatment through the InCise™ Multileaf Collimator (MLC) for the CyberKnife® M6™ Radiosurgery System at Mercy Health Lacks Cancer Center on Monday, March 2, 2015. To prepare for this new technology, Mercy Health Lacks Cancer Center participated as one of only three evaluation sites in the world for this treatment system.
The InCise MLC is the world’s first multileaf collimator to be available on a robotic platform, designed to deliver extremely precise stereotactic body radiation therapy (SBRT). Using its unique robotic range of motion and continuous image guidance, the system follows the target throughout the treatment process, delivering individualized treatment with sub-millimeter precision. The Mercy Health CyberKnife can treat tumors in the prostate, lung, brain, spine, liver, pancreas and kidney, and may offer hope to patients who have inoperable or surgically complex tumors.
“We are very excited to offer this new tool to our patients in their fight against cancer,” said Gil Padula, MD, medical director of Mercy Health CyberKnife. “We anticipate being able to use the Multileaf Collimator for about 80% of our CyberKnife patients, resulting in a shorter treatment time for those individuals. The multileaf collimator allows CyberKnife to be even more precise than conventional robotic radiosurgery, allowing much more efficient treatment of tumors of complex shapes.”
The multileaf collimator refers to the shape of the treatment beam and provides clinicians greater flexibility with treatment delivery. Before MLC became available, the collimator’s shape was round. Now, with the “multileaf” design, treatment beams better conform to the shape of the tumor and avoid adjacent sensitive regions.
“The benefits of the Multileaf Collimator are multi-faceted,” said Tewfik Bichay, PhD, medical physicist at Mercy Health Lacks Cancer Center. “The treatment time will decrease for the average patient by about 30%, the dose to neighboring regions is also greatly reduced, and the number of treatment beams required is reduced by about 65%. Overall the patient is treated more accurately, quicker, and the normal tissues are better spared during the course of treatment.”
If you would like more information on the Mercy Health CyberKnife, please visit www.mercyhealthcyberknife.com.